For the quarter ending 2026-03-31, TVRD had -$883K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -6,804 | -7,275 | -5,527 | -5,412 |
| Depreciation and amortization expense | 24 | 24 | 24 | 47 |
| Interest accrued on convertible notes | - | 0 | 0 | 651 |
| Stock-based compensation expense | 370 | 353 | 339 | 707 |
| Change in fair value of convertible notes | - | 0 | 0 | -7,810 |
| Non-cash lease expense | 20 | 19 | 18 | 35 |
| Accretion of net discounts on short-term investments | 35 | 34 | 25 | 141 |
| Prepaid expenses and other assets | -382 | -1,256 | -153 | 1,717 |
| Accounts payable and accrued expenses | 212 | 0 | 787 | 132 |
| Operating lease liabilities | -28 | -28 | -26 | -49 |
| Net cash used in operating activities | -5,859 | -5,685 | -4,257 | -13,557 |
| Purchases of short-term investments | - | 0 | 0 | 31,486 |
| Maturities of short-term investments | 4,976 | 5,000 | 5,349 | 11,053 |
| Net cash provided by (used in) investing activities | 4,976 | 5,000 | 5,349 | -20,433 |
| Cash acquired in connection with the merger | - | 0 | 0 | 24,992 |
| Payments for merger transaction costs | - | 0 | 429 | 2,392 |
| Proceeds from exercise of stock options | - | 1 | 107 | 424 |
| Net cash provided by financing activities | - | 1 | -322 | 23,024 |
| Net decrease in cash and cash equivalents | -883 | -684 | 770 | -10,966 |
| Cash and cash equivalents - beginning of year | 20,734 | 21,418 | 31,614 | - |
| Cash and cash equivalents - end of period | 19,851 | 20,734 | 21,418 | - |
Tvardi Therapeutics, Inc. (TVRD)
Tvardi Therapeutics, Inc. (TVRD)